Close Menu

financial results

The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.

The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.

The company reported a doubling of its third quarter revenues on strong demand for its sexually transmitted disease testing products.

The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.

The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.

Revenues at BioReference Labs fell short in the quarter but are expected to grow in the fourth quarter and next year, the company said

Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.

Total revenues were $699,000 up from $623,000 the year before with product revenue up 13 percent as OVA1 sales volume dropped but revenue per test performed rose.

Third quarter growth was driven by a sharp increase in revenues from HTG Molecular's pharmaceutical partners.

For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.